Volume 44 Issue 1, January 2023

Schematic depicting the preparation of a dual-responsive nanoparticle BCGN and its mechanisms in treating non-small-cell lung cancer (NSCLC). The BCGN are responsive to oxidation and reduction for triggering drug release at different conditions. It provides a promising strategy to improve combinational molecular targeted therapy against NSCLC.